2,104
Participants
Start Date
December 4, 2000
Primary Completion Date
February 10, 2014
Study Completion Date
March 17, 2014
epoetin alfa
40,000 IU
filgrastim
5 mg/kg/d - days 2-13
cyclophosphamide
75, 600 and 830 mg/m2
doxorubicin hydrochloride
60 mg/m2
epirubicin hydrochloride
60 mg/m2
fluorouracil
500mg/m2
paclitaxel
175 mg/m2
Staten Island University Hospital, Staten Island
Our Lady of Mercy Medical Center, The Bronx
Advanced Oncology Associates, Armonk
Hematology Oncol. Associates Rockland, Nyack
Queens Medical Associates, PC, Fresh Meadows
Winthrop University Hospital Onc/Hem, Mineola
University of Rochester, Rochester
Pottstown Memorial Regional Cancer Centre, Pottstown
Sibley Memorial Hospital, Oncology Research, Washington D.C.
Suburban Hospital Cancer Program, Bethesda
Associates in Oncology/Hematology, Rockville
Saint Joseph Medical Center, Cancer Care Program, Towson
Arlington-Fairfax Hematology Oncology P.C., Arlington
Duke University Medical Center, Durham
ECU School of Medicine, Leo Jenkins Cancer Center, Greenville
Santee Hematology Oncology, Sumter
Florida Oncology Associates, Orange Park
Comprehensive Cancer Care Centre at Boca Raton, Boca Raton
University Oncology and Hematology Associates, Chattanooga
Consultants in Blood Disorders and Cancer, Louisville
Lexington Oncology Assts./Central Baptist Hospital, Lexington
Oncology/Hematology Care, Inc., Cincinnati
Therapy Associates, Inc., Hematology/Oncology, Evansville
University of Minnesota Cancer Centre, Minneapolis
St. Luke's Cancer Care Centre, Duluth
Columbia-Capitol Comprehensive Care Clinics, Jefferson City
Nebraska Methodist Hospital, Omaha
Creighton University Cancer Centre, Omaha
CHRISTUS Schumpert Medical Center - Hem/Onc Clinic, Shreveport
Hematology Oncology Services of Arkansas, Little Rock
Sparks-Arkansas Oklahoma Cancer Treatment Centre, Fort Smith
Center for Oncology Research and Treatment, Dallas
Lone Star Oncology Consultants, PA, Austin
Northern Utah Associates, Ogden
Scripps Cancer Center, La Jolla
University of Colorado Cancer Centre, Aurora
Greenwich Hospital - Bendheim Cancer Center, Greenwich
University of Florida, Gainesville
The University of Chicago Medical Center, Chicago
Willis-Knighton Cancer Center, Shreveport
Maine Center for Cancer Medicine and Blood Disorders, Scarborough
Maine General Medical Center, Waterville
Baystate Regional Cancer Program, Springfield
Saint Louis University Hospital, St Louis
Tom Baker Cancer Centre, Calgary
BCCA - Cancer Centre for the Southern Interior, Kelowna
BCCA - Fraser Valley Cancer Centre, Surrey
BCCA - Vancouver Cancer Centre, Vancouver
CancerCare Manitoba, Winnipeg
The Moncton Hospital, Moncton
Atlantic Health Sciences Corporation, Saint John
Dr. H. Bliss Murphy Cancer Centre, St. John's
QEII Health Sciences Center, Halifax
The Royal Victoria Hospital, Barrie
Northeast Cancer Center Health Sciences, Greater Sudbury
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
Grand River Regional Cancer Centre, Kitchener
London Regional Cancer Program, London
Lakeridge Health Oshawa, Oshawa
Ottawa Health Research Institute - General Division, Ottawa
Algoma District Cancer Program, Sault Ste. Marie
The Scarborough Hospital, Scarborough Village
Niagara Health System, St. Catharines
Thunder Bay Regional Health Science Centre, Thunder Bay
Odette Cancer Centre, Toronto
St. Michael's Hospital, Toronto
Mount Sinai Hospital, Toronto
Univ. Health Network-Princess Margaret Hospital, Toronto
Trillium Health Centre - West Toronto, Toronto
Windsor Regional Cancer Centre, Windsor
PEI Cancer Treatment Centre,Queen Elizabeth Hospital, Charlottetown
Hopital Charles LeMoyne, Greenfield Park
Hopital Maisonneuve-Rosemont, Montreal
CHUM - Hopital Notre-Dame, Montreal
CHUM - Hotel Dieu du Montreal, Montreal
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Lead Sponsor
North Central Cancer Treatment Group
NETWORK
SWOG Cancer Research Network
NETWORK
Cancer and Leukemia Group B
NETWORK
NCIC Clinical Trials Group
NETWORK